FDA refuses to review Alkermes' depression treatment, seeks more trials

(Reuters) - Alkermes Plc's application for approval of an experimental depression drug has been rejected by the U.S. Food and Drug Administration due to a lack of evidence of its effectiveness.

from Reuters: Health News https://ift.tt/2Edzknv